ABO-incompatible heart transplantation in infants

N Engl J Med. 2001 Mar 15;344(11):793-800. doi: 10.1056/NEJM200103153441102.

Abstract

Background: Transplantation of hearts from ABO-incompatible donors is contraindicated because of the risk of hyperacute rejection mediated by preformed antibodies in the recipient to blood-group antigens of the donor. This contraindication may not apply to newborn infants, who do not yet produce antibodies to T-cell-independent antigens, including the major blood-group antigens.

Methods: We studied 10 infants 4 hours to 14 months old (median, 2 months) who had congenital heart disease or cardiomyopathy and who received heart transplants from donors of incompatible blood type between 1996 and 2000. Serum isohemagglutinin titers were measured before and after transplantation. Plasma exchange was performed during cardiopulmonary bypass; no other procedures for the removal of antibodies were used. Standard immunosuppressive therapy was given, and rejection was monitored by means of endomyocardial biopsy. The results were compared with those in 10 infants who received heart transplants from ABO-compatible donors.

Results: The overall survival rate among the 10 recipients with ABO-incompatible donors was 80 percent, with 2 early deaths due to causes presumed to be unrelated to ABO incompatibility. The duration of follow-up ranged from 11 months to 4.6 years. Two infants had serum antibodies to antigens of the donor's blood group before transplantation. No hyperacute rejection occurred; mild humoral rejection was noted at autopsy in one of the infants with antibodies. No morbidity attributable to ABO incompatibility has been observed. Despite the eventual development of antibodies to antigens of the donor's blood group in two infants, no damage to the graft has occurred. Because of the use of ABO-incompatible donors, the mortality rate among infants on the waiting list declined from 58 percent to 7 percent.

Conclusions: ABO-incompatible heart transplantation can be performed safely during infancy before the onset of isohemagglutinin production; this technique thus contributes to a marked reduction in mortality among infants on the waiting list.

Publication types

  • Clinical Trial

MeSH terms

  • ABO Blood-Group System / immunology*
  • Blood Group Incompatibility*
  • Cardiomyopathies / mortality
  • Cardiomyopathies / surgery*
  • Graft Rejection / immunology
  • Heart Defects, Congenital / mortality
  • Heart Defects, Congenital / surgery*
  • Heart Transplantation / adverse effects
  • Heart Transplantation / immunology*
  • Heart Transplantation / mortality
  • Hemagglutinins / blood
  • Histocompatibility
  • Humans
  • Immunosuppression
  • Infant
  • Infant, Newborn
  • Survival Rate
  • Waiting Lists

Substances

  • ABO Blood-Group System
  • Hemagglutinins